Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo PLATINUM™ Functional Grade

Clone YTS-169 is used in in vivo mouse studies primarily for the depletion of CD8? T cells. Researchers inject the antibody into mice to selectively target and remove CD8-positive cells, such as cytotoxic T lymphocytes, to study immune function or modulate immune responses.

Key details on its in vivo use:

• Target: YTS-169 is a rat monoclonal antibody specific for mouse CD8?, which is expressed on CD8? T lymphocytes.
• Application: The main in vivo application of YTS-169 is depletion of CD8? cells. This approach is used experimentally to abolish CD8-mediated immune functions, such as cytotoxic activity, or assess the role of CD8? T cells in disease models or immune memory.
• Administration: Mice are typically injected with YTS-169 antibody, at doses that can range, for example, around 0.5 mg per mouse per dose as referenced in published studies. The dosing, concentration, and schedule may vary depending on experimental design and mouse strain.
• Specificity: Unlike certain anti-CD8 clones (such as 2.43), YTS-169 binds CD8? in all mouse strains, ensuring broad applicability for depleting CD8? cells in immunological studies.
• Additional Applications: The antibody may also be used for immunohistochemistry on frozen tissue sections or in flow cytometry (FC), but its primary cited in vivo use is for cell depletion.
• Formulation: For in vivo work, low endotoxin formulations are necessary to minimize non-specific inflammatory effects. These are commercially available and are typically stored at ?80°C for long-term use.

Summary of research uses:

• CD8? cell depletion to assess their role in immune responses.
• Functional studies in tumor models, infection, and autoimmunity via removal of cytotoxic T cells.
• Immunological assays requiring confirmed absence of CD8? cells after depletion.

Experimental caveats: Investigators must optimize concentration for their specific application and confirm depletion efficacy, as residual CD8? cells may affect results. Only for research use—not therapeutic or diagnostic.

In short: YTS-169 is a critical tool for in vivo CD8? T cell depletion studies in mice, enabling researchers to dissect T cell functions and immune mechanisms.

The YTS-169 antibody is most commonly used as a mouse anti-CD8? monoclonal antibody, especially in immunological studies involving murine T cell populations. In the literature, several other antibodies and proteins are often used in combination or for comparative purposes with YTS-169:

• 2.43 antibody: Another anti-mouse CD8? antibody, but with different epitope specificity (Lyt2.2-specific), whereas YTS-169 recognizes both Lyt2.1 and Lyt2.2 alleles. These two antibodies are frequently compared or used together to distinguish between CD8? variants on different mouse strains.

• Anti-CD4 antibodies: Generally used for T cell subset discrimination in flow cytometry. An example is PE-conjugated anti-CD4, regularly paired with YTS-169 for CD8 and CD4 T cell identification.

• Recombinant CD8 fusion proteins: Used to assess binding properties of YTS-169 and other antibodies, such as recombinant soluble CD8?? heterodimer fusion proteins in affinity studies.

• Other anti-CD8 variants: Sometimes, additional anti-CD8 clones (e.g., YTS156 for Lyt3 specificity) may be included in panels to differentiate or validate specificity of YTS-169.

These antibodies and proteins are typically utilized in flow cytometry, immuno-PET imaging, and in vitro binding studies for thorough analysis of murine T cell populations and to compare affinity or specificity across strains and CD8 epitopes.

Clone YTS-169 (also cited as YTS169.4) is a rat monoclonal antibody widely used in scientific literature for identifying and depleting mouse CD8+ T cells in various immunological assays, particularly flow cytometry and in vivo depletion studies.

Key findings and uses in the literature:

• Specificity and Target: YTS-169 recognizes the CD8 alpha (CD8a) chain, pivotal for identifying CD8+ T lymphocytes, which are critical for cytotoxic immune responses.
• Flow Cytometry and Depletion: The antibody is highly cited for staining and depleting CD8+ T cells in mouse models, aiding in studies of T cell function, antitumor immunity, and immune cell subset analysis.
• Functional Studies: In crucial immuno-oncology research, YTS-169 has enabled:
  • The functional depletion of CD8+ T cells in vivo to examine the role of these cells in tumor rejection or response to immunotherapies.
  • Delineation of mechanisms of resistance to T cell-mediated killing in cancer, as seen in CRISPR screens identifying genes (e.g., Ifngr2, Jak1) that render tumor cells resistant to CD8+ T cell attack when knocked out.
• Citation Prevalence: The clone is cited in over 95 publications across immunological and cancer biology fields, signifying its standardization and reliability in mouse immune research.
• Technical Details: It is used at concentrations such as ?0.2 ?g per 10^6 cells for flow cytometry and 1–10 ?g/ml for western blotting. It is also compatible with various secondary antibodies and detection platforms for multiparameter cell analysis.

In summary, scientific literature consistently demonstrates the utility of YTS-169 in defining, quantifying, and functionally manipulating CD8+ T cells in mouse immunology, thus driving advances in fields like tumor immunology, vaccine responses, and T cell biology research.

Dosing regimens of clone YTS-169 (YTS169.4) for CD8+ T cell depletion in mice commonly range from low hundreds of micrograms up to 1 mg per mouse per dose, but specific protocols are tailored based on mouse strain, disease model, route of administration, and experimental goals.

Key context and supporting details:

• YTS-169.4 is a rat IgG2b monoclonal antibody targeting the murine CD8 cell surface antigen and is widely used for in vivo depletion of CD8+ T cells in mouse models.
• While direct, comprehensive dosing regimens for YTS-169.4 across multiple mouse models are not detailed in the provided sources, standard usage patterns from closely related literature and antibody suppliers generally recommend single doses ranging from 100–500??g/mouse, administered via intraperitoneal (i.p.) or intravenous (i.v.) injection, with repeat dosing every 3–7 days as needed for sustained depletion.
• The frequency and amount may be adjusted:
  • For acute depletion (e.g., prior to challenge, transplantation, or tumor inoculation), a single dose is often sufficient.
  • For chronic or longitudinal studies, repeat dosing (for example, twice weekly) may be used to ensure persistent CD8+ T cell absence.
• Experimental variables: Dosing can be influenced by the immune status of the mouse strain, tumor burden, infection model, or concurrent therapies. Some immunocompromised or tumor-bearing strains may require lower or less frequent dosing, while highly immunocompetent models or rapidly progressive diseases may need higher or more frequent administration.
• Comparative information: For other depleting anti-CD8 antibodies such as clone 2.43 and 53-6.7, recommended regimens are generally 100–500??g/mouse i.p. or i.v., with maintenance every 3–7 days, suggesting YTS-169.4 is used in similar fashion.

Storage and handling:

• Clone YTS169.4 is supplied at 1?mg/mL in PBS, and the manufacturer recommends aliquoting and storage at ?20°C (long term) or 2–8°C (short term).

Limitations:

• The precise comparative data for dosing across different mouse strains or disease models with YTS-169.4 is not present in the sources. Most publications adapt dose and frequency based on pilot experiments or reference protocols for similar clones. Optimization for new models is advised.

In summary, YTS-169.4 is administered to mice at doses of 100–500??g per mouse per injection, with adjustments based on model, desired depletion kinetics, and experimental duration. Routine schedules use repeat doses every 3–7 days for sustained depletion. Consult the latest specific literature or pilot data for fine-tuning in unusual or highly sensitive models.